Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Revive Therapeutics Ltd. is a Canadian life sciences company focused on drug development and commercialization across biotechnology, pharmaceuticals, and mental health therapeutics, with an emphasis on infectious diseases and psychedelic-assisted therapies. The company’s activities center on identifying, developing, and repurposing novel and existing drug candidates for unmet medical needs, particularly in areas with limited effective treatments.
Revive’s primary revenue drivers are research and development programs rather than product sales, as the company remains in the clinical and pre-commercial stages. Its strategy emphasizes rapid development pathways through drug repurposing and regulatory efficiency. The company was founded in 2018 and initially focused on cannabinoid-based therapeutics before expanding into psychedelic compounds and infectious disease treatments, most notably during the COVID‑19 pandemic.
Business Operations
Revive Therapeutics operates through multiple internal development programs spanning infectious disease therapeutics and psychedelic-based mental health treatments. Its most prominent asset has been Bucillamine, an orally administered small-molecule drug evaluated for the treatment of COVID‑19 and other inflammatory conditions. The company also maintains a psychedelic program focused on psilocybin and related compounds for mental health and neurological indications.
Operations are primarily research-driven, with clinical trials, regulatory submissions, and intellectual property management forming the core activities. Revive conducts its development work through a combination of internal management and external clinical research organizations, and it controls a portfolio of drug rights, formulations, and patents rather than large-scale manufacturing infrastructure. The company does not report material commercial partnerships generating operating revenue, and available public disclosures indicate no significant joint ventures with revenue-producing subsidiaries.
Strategic Position & Investments
Revive’s strategic direction centers on leveraging accelerated regulatory pathways, orphan or emergency-use opportunities, and drug repurposing to reduce development risk and timelines. The company has invested heavily in clinical-stage assets rather than acquiring revenue-generating businesses, reflecting a high-risk, high-reward biotechnology profile.
Its investment focus includes infectious disease response platforms, psychedelic compounds for mental health, and inflammation-related therapies. While Revive has announced research collaborations and licensing arrangements related to its pipeline assets, publicly available disclosures do not confirm large-scale acquisitions or controlling stakes in independently operating portfolio companies. Data inconclusive based on available public sources regarding the long-term commercial viability of its current pipeline.
Geographic Footprint
Revive Therapeutics is headquartered in Canada, with corporate offices in Vancouver, British Columbia. Its operational footprint is primarily North American, with clinical development activities conducted in Canada and the United States through contracted research sites and regulatory engagement with Health Canada and the U.S. Food and Drug Administration.
The company does not report significant physical operations outside North America, but its intellectual property strategy and clinical ambitions are intended to support future commercialization in global pharmaceutical markets, including potential expansion into Europe and other international regions subject to regulatory approvals.
Leadership & Governance
Revive is founder-led and governed by a management team with experience in biotechnology development, capital markets, and life sciences strategy. Leadership emphasizes capital efficiency, regulatory navigation, and rapid advancement of clinical-stage assets as core elements of its operating philosophy.
Key executives include:
- Michael Frank – Chief Executive Officer
- Michael Frank – Chairman of the Board
- Roberto Bellini – Chief Financial Officer
- Stephen Burns – Director
- Gerry Goldstein – Director
The board and executive team collectively guide corporate strategy, capital allocation, and clinical prioritization, with governance structured around public company compliance and shareholder oversight.